These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 27312037)
1. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients aged 75 years and over: Spanish group of peritoneal cancer surgery (GECOP) multicenter study. Cascales-Campos PA; López-López V; Muñoz-Casares FC; Feliciangeli E; Torres Melero J; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Gil J Surg Oncol; 2016 Jun; 25(2):111-6. PubMed ID: 27312037 [TBL] [Abstract][Full Text] [Related]
2. Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP). Cascales-Campos PA; López-López V; Torres-Melero J; Arjona A; Muñoz-Casares FC; Barrios P; Morales R; Pereira F; Bretcha-Boix P; González-Bayón L; González-Moreno S; Gil J Clin Transl Oncol; 2020 Jan; 22(1):130-136. PubMed ID: 31049819 [TBL] [Abstract][Full Text] [Related]
3. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852 [TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified? López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240 [TBL] [Abstract][Full Text] [Related]
5. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center. Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715 [TBL] [Abstract][Full Text] [Related]
6. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy. Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223 [TBL] [Abstract][Full Text] [Related]
7. Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement. Franssen B; Tabrizian P; Weinberg A; Romanoff A; Tuvin D; Labow D; Sarpel U Ann Surg Oncol; 2015 May; 22(5):1639-44. PubMed ID: 25216604 [TBL] [Abstract][Full Text] [Related]
8. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [TBL] [Abstract][Full Text] [Related]
9. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ihemelandu CU; McQuellon R; Shen P; Stewart JH; Votanopoulos K; Levine EA Ann Surg Oncol; 2013 Oct; 20(11):3519-26. PubMed ID: 23748607 [TBL] [Abstract][Full Text] [Related]
10. Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center. Graziosi L; Marino E; De Angelis V; Rebonato A; Donini A World J Surg Oncol; 2016 Mar; 14():97. PubMed ID: 27036213 [TBL] [Abstract][Full Text] [Related]
11. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes. Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038 [TBL] [Abstract][Full Text] [Related]
12. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience. Alzahrani NA; Valle SJ; Fisher OM; Sugarbaker PH; Yonemura Y; Glehen O; Goere D; Honore C; Brigand C; de Hingh I; Verwaal VJ; Deraco M; Baratti D; Kusamura S; Pocard M; Piso P; Maerz L; Marchal F; Moran B; Levine EA; Dumont F; Pezet D; Abboud K; Kozman MA; Liauw W; Morris DL; J Surg Oncol; 2019 Mar; 119(3):336-346. PubMed ID: 30554404 [TBL] [Abstract][Full Text] [Related]
13. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149 [TBL] [Abstract][Full Text] [Related]
14. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ihemelandu C; Bijelic L; Sugarbaker PH Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250 [TBL] [Abstract][Full Text] [Related]
15. Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Konstantinidis IT; Chouliaras K; Levine EA; Lee B; Votanopoulos KI Ann Surg Oncol; 2017 Dec; 24(13):3825-3830. PubMed ID: 29019118 [TBL] [Abstract][Full Text] [Related]
16. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386 [TBL] [Abstract][Full Text] [Related]
17. Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. Tabrizian P; Jibara G; Shrager B; Franssen B; Yang MJ; Sarpel U; Hiotis S; Labow D Surg Oncol; 2013 Sep; 22(3):184-9. PubMed ID: 23827047 [TBL] [Abstract][Full Text] [Related]
18. Preoperative Nutrition Status and Postoperative Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Reece L; Dragicevich H; Lewis C; Rothwell C; Fisher OM; Carey S; Alzahrani NA; Liauw W; Morris DL Ann Surg Oncol; 2019 Aug; 26(8):2622-2630. PubMed ID: 31123932 [TBL] [Abstract][Full Text] [Related]
19. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer. Cascales Campos P; Gil J; Parrilla P Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502 [TBL] [Abstract][Full Text] [Related]
20. Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters. Simkens GA; van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH Ann Surg Oncol; 2016 Jan; 23(1):99-105. PubMed ID: 26148758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]